WASM HUGE, BUYYYYYY~~DIRECTORS, NOMINEES, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS
The following sets forth information about our directors, nominees and executive officers as of the date of this report:
Name Age Position
James R. Garvin, PhD 70 Chief Executive Officer, President, and Director
Thomas Knott, PhD 50 Chief Science Officer and Director
Henry C. Bourg, CPA 56 Chief Financial Officer
Paul Castella, PhD (1) 52 Director
Ian Clements (1) 56 Director
Alan Dean (1) 71 Director
Shing Leong Hui (1) 60 Director
Sue Lynn Hui (1) 42 Director
(1) Drs. Castella and Knott and Messrs. Clements, Dean and Hui and Ms. Hui will become directors on the tenth day following the mailing of the Information
Statement to our stockholders, which such mailing is expected to occur on or about March 22, 2018. Steven Anderson, Brian L. Klemsz, and Joni K. Troska have
resigned from the Board effective as of the tenth day following the mailing of the Information Statement and, accordingly, are excluded from this table and the
below disclosures.
James R. Garvin, PhD, Chief Executive Officer, President and Director
James R. Garvin has served as the CEO, President and a Director of CytoBioscience since March 2015. Dr. Garvin has twenty-nine years of experience in working
in the biotech sector and finance. His work has been recognized by the French Academy of Science and he was named one of sixteen healthcare innovators in the
state of Texas for 2017. As a former investment banker, he has worked on a number of different biotechnology acquisitions, in the US, Europe and in Israel. He has
been a board member of a number of companies and currently is on the board of the Zerah Foundation which provides educational opportunities for
underprivileged children in India. His international range of experiences and interests has been diverse but this has allowed him to have an outside of the box
perspective that has served him well in working with companies and situations over the years.
Dr. Garvin received his PhD in Economic Systems from the University of New Orleans, as well as his Masters in Administration and his BA (Hons) in English and
International Relations from the State University of New York, Albany
Thomas Knott, PhD, Chief Science Officer
Thomas Knott, PhD has served as the Chief Science Officer of CytoBioscience since March 2015. Dr. Thomas Knott is an innovative technology driven
entrepreneur who founded Cytocentrics CCS GmbH, a high-tech scientific instrumentation and biotech company specializing in the field of ion channel
electrophysiology in 2001. Dr. Knott single-handedly developed the Cytocentrics instrument for ion channel analysis, the CytoPatch™, demonstrating a more
complete feature set in patch clamp capabilities than any existing manual patch clamp system (whole cell voltage clamp and current clamp, perforated patch clamp,
extracellular and intracellular perfusion, temperature control, fast ligand gated ion channels, mechano-stimulation, GLP, and network capability). He has worked
with three Nobel Prize winning teams.
- 4 -
Henry C. Bourg, CPA, MBA, Chief Financial Officer
Henry C. Bourg, CPA, MBA, has served as the CFO of CytoBioscience since September 2017. Henry Bourg is an accomplished senior finance and accounting
professional with over thirty years' experience with start-ups, mid-sized and multi-billion dollar global organizations. He started his career with Ernst & Young in
Texas and later in Maryland and New York. While with Ernst & Young, he served primarily financial institution clients such as American General Life Insurance,
Capital One and MBNA America Bank. In addition to his public accounting experience, Henry has served in senior finance and accounting roles with the US
Government in Europe; The Shaw Group, Chicago Bridge & Iron, and Westinghouse Electric Company in Asia; Inktomi Corporation and Bookham, Inc. (now
Oclaro) as well as several technology start-ups in Silicon Valley. He earned his Bachelor of Science degree in Accounting from Louisiana State University and a
Master of Business Administration from Santa Clara University . Paul Castella, PhD, MBA, Director
Dr. Paul Castella is the co-founder and CEO of Santalis Pharmaceuticals, Inc. a clinical stage drug development company. Santalis is a wholly owned subsidiary of
Quintis Ltd., which acquired the business in 2015, along with ViroXis Corporation (which Paul co-founded in 2008). Previously, Paul co-founded and managed a
number of other life science businesses, including; CardioSpectra, Inc., which was acquired by Volcano Corporation (NASDAQ: VOLC) in December 2007;
Xenotope Diagnostics, Inc., which developed the only FDA approved rapid test for Trichomonas (sold worldwide under the OSOM ® brand), the world's most
prevalent non-viral sexually transmitted disease; BiO2 Medical, Inc., which developed the Angel ® Catheter, the first device indicated for the prevention of
pulmonary embolism (PE) in hospitalized patients; and the San Antonio-based Targeted Technology Funds, which focus on early-stage life science investing,
including an investment in CytoBioscience.
Paul received his PhD in cell biology and genetics from Cornell University Medical College in Manhattan, his MBA from the University of Texas at San Antonio,
a BSc (Hons) in biochemistry the University of London, and has been granted ten US patents.
Ian Clements, MSc., Director
Ian Clements has over 25 years of commercial, corporate and business development experience in the pharmaceutical and biotechnology industries including sales
and marketing, medical affairs, product and clinical development, program management as well as commercial, corporate and business development.
Ian is the co-founder and COO of Santalis Pharmaceuticals and the co-founder and former CEO of ViroXis Corporation. Ian served for six years as Head of
Commercial Operations and Corporate Development for ILEX Oncology in San Antonio where he established the new Business Development and Medical Affairs
departments during the launches of Campath and Clorfarabine. Previously, Ian has served as the Head of Oncology Product Management at Lederle labs in UK,
Head of Global Oncology Product Management at the Upjohn company where he managed the global launch of Camptosar and Head of US Oncology Marketing
for Novartis, managing their oncology portfolio with over $2 billion in sales and launching 3 oncology products in his tenure.
Ian received his BS (Hons) degree in Genetics from Swansea University, UK and his MS. in Immunology from King's College, London, UK.
- 5 -
Alan Dean, MBA, Director
Alan Dean is a senior technology executive with over 40 years of experience in the technology development industry. He was employed for more than 25 years at
Southern Research Institute where he became Vice-President, Commercialization, and was a principal in the first commercial spin-off companies from the
Institute. As the co-founder and COO of SBS, one of the subsidiaries in the holding company he co-founded, Alan was responsible for the buyout and integration
of Birmingham Polymers, Inc., a Bristol-Myers-Squibb affiliate. SBS was subsequently acquired by Durect Corp. of California in 2001 in a transaction valued at
$35 million. He has been an advisor to, and board member of, numerous technology companies, past and present. Alan is the co-founder and senior managing
partner of the Targeted Technology Fund I and II, and was previously a Managing Partner of the Birmingham Technology Venture Fund.
Shing Leong Hui, MBA, Director
Shing Leong Hui has over thirty years' experience in the Electronics Manufacturing Services Industry. He is currently the Chairman of the Supervisory Board of
Payer International Technologies GmbH where he has served since June 2002. He is the co-founder of Neutronics Electronic Industries Holding A.G., which has
been subsequently acquired by Flex Ltd. (previously known as Flextronics) and was a previous Flextronics board member. Today, he is widely involved with
companies which are based in Eastern Europe and China. He has a long association with Cytocentrics and was one of the original investors when it was based in
Rostock, Germany.
He has an MBA from the University of Michigan and a B.Sc in Chemical Engineering from the University of Birmingham, UK.
Sue Lynn Hui, Director
Sue Lynn Hui has over six years of European and Asian experience in the Pharmaceuticals, Communications and Technology and Oil and Gas sectors. She has
served as an advisory member of Payer since March 2017. She was a Manager in her previous role at A.T Kearney from 2002 to 2007. She is an advisory board
member of Payer International Technologies GmbH.
She graduated with First Class Honors in Master of Engineering in Chemical Engineering from Imperial College London, UK.
Family Relationships
Shing Leong Hui and Sue Lynn Hui are father and daughter.
- 6
